Industry Research

ISR asked outsourcers of sterile injectable drug product to identify their biggest challenge when outsourcing to CDMOs/CMOs. We were surprised to see a nearly four-way tie in the results. In this article, we’ll take a closer look at one of these challenges.

Nearly two-thirds of clinical development studies are currently using a software vendor-designed eTMF application. A slight increase (71%) is expected three years from now.

We asked 100 decision-makers in the pharmacovigilance space where in the adoption curve of new technologies they see their organizations with respect to AI in pharmacovigilance.

In a recent study, 4 percent of respondents reported using a sole sourcing model, whereby sponsors select a single central lab for all their testing needs.

ISR recently asked site startup experts about their company’s stance on virtual trials.

ISR asked respondents at sponsor organizations, CROs, and site management organizations (SMOs) about a variety of start-up strategies and how frequently each is employed at their company.

In a recent survey targeting companies that outsource clinical logistics, ISR asked respondents to indicate the proportion of clinical services they have outsourced in the past year and what they estimate the proportion will look like in three years.

While pharma companies, biotechs, and CROs are expanding their use of mHealth technologies, they are not expanding the use of it evenly across all therapeutic areas.

A critical factor when examining service provider selection is the existence of preferred provider agreements. Keeping this in mind, ISR asks respondents to share their selection criteria in a way that demonstrates these agreements’ impacts on the decision-making process.

For companies considering life cycle extension strategies for their oral-dose products, there are clear preferences as to which strategies they would pursue.

ISR research indicates that proactive communication between sponsors and CMOs in these three areas will help to improve outsourcing relationships. Data comes from ISR’s Development and Commercial Outsourcing Models market research report.

As part of our yearly service provider quality benchmarking, Industry Standard Research asks late-phase decision makers to select their top five most important attributes when outsourcing with no preferred providers.

Outsourcing motivations are important considerations to identifying the best outsourcing approach and should influence the type of relationships your organization develops with CMOs. Data comes from ISR’s CMO Quality Benchmarking suite of market research reports and ISR’s Development and Commercial Outsourcing Models market research report.

ISR surveyed hundreds of clinical development outsourcers about what they consider important when selecting providers. To capture the increasing role that preferred provider agreements are playing in the selection process, respondents were asked about attribute importance in several scenarios.

Almost half of survey respondents report their companies use formal preferred provider agreements (PPAs) for their Phase 2/3 outsourcing.

ISR recently surveyed decision makers across all phases of clinical development to gain insight on sponsor/CRO dynamics. More than half of respondents agreed (to some level)that their organization would change its mix of CROs.

ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.

A look at which departments at sponsor organizations are involved in the decision-making process and how much decision-making responsibility each department has for outsourcing various late-phase study activities.

A hypertree showing the network of connections between 2017’s top-selling oncology products. Oncology drugs made up 13 of last year’s top 50 selling products.

Understanding which attributes industry peers feel are important can help in the process of CRO selection.